In a pooled analysis of 3170 NSCLC patients (9.2% with treated and stable BM), those treated with pembrolizumab had a greater OS than those receiving chemotherapy, regardless of whether PD-L1 expression (reported as TPS) was ≥50% or, less stringently, ≥1% [35]. Here, CD274 is linked to non-small cell lung carcinoma.